Soleno Therapeutics (SLNO) AI Stock Analysis

• Market Cap: $2.25B
• Dividend Yield: N/A
• Average Volume (3M): 1.43M
• Price to Earnings (P/E): ―
• Beta (1Y): 0.47
• Revenue Growth: N/A
• EPS Growth: 44.84%
• Country: US
• Employees: 115
• Sector: Healthcare
• Sector Strength: 45
• Industry: Biotechnology
• EPS (TTM): 0.47
• Shares Outstanding: 53,710,026
• 10 Day Avg. Volume: 1,883,670
• 30 Day Avg. Volume: 1,433,293
• PEG Ratio: -0.12
• Price to Book (P/B): 7.37
• Price to Sales (P/S): 0.00
• P/FCF Ratio: -26.05
• Enterprise Value/Market Cap: 1.45
• Enterprise Value/Revenue: 33.10
• Enterprise Value/Gross Profit: 33.73
• Enterprise Value/Ebitda: -49.26
• 1Y Price Target: $105.13
• Price Target Upside: 150.61% Upside
• Rating Consensus: Strong Buy
• Number of Analyst Covering: 8
• EPS Forecast (FY): 4.1
• Revenue Forecast (FY): $468.77M

• Rating: 53 Neutral
• Price Target: $42.00 ▲(0.12% Upside)

The score is driven mainly by mixed financial performance—strong revenue inflection and an excellent balance sheet, but still meaningful losses and cash burn in the TTM view. Technicals are notably weak (below major moving averages with negative MACD), while the latest earnings call was constructive (profitability, adoption, and payer coverage) but tempered by discontinuations and short-seller-related disruption.

Positive Factors

Solid Equity Base

A strong equity base provides financial stability, offering a cushion for ongoing R&D expenses and potential future investments.

Minimal Debt

Minimal debt levels reduce financial risk and interest obligations, allowing more resources to be allocated towards product development.

Focus on Rare Diseases

Targeting rare diseases can lead to market exclusivity and pricing power, enhancing long-term revenue potential upon successful product launch.

Negative Factors

Lack of Revenue

The absence of revenue generation indicates reliance on external funding, posing a risk to financial sustainability if product development is delayed.

Negative Cash Flow

Negative cash flow highlights ongoing cash burn, necessitating continuous external financing, which may dilute existing shareholders over time.

High Net Losses

Substantial net losses without offsetting revenue can strain financial resources, impacting the company's ability to sustain long-term operations.

Soleno Therapeutics Business Overview & Revenue Model

Company Description

Soleno Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of novel therapeutics for the treatment of rare diseases. Its lead candidate is Diazoxide Choline Controlled-Release, a once-daily oral tablet for the treatment of Prader-Willi Syndrome, which is being evaluated in an ongoing Phase III clinical development program. The company was formerly known as Capnia, Inc. and changed its name to Soleno Therapeutics, Inc. in May 2017. Soleno Therapeutics, Inc. was incorporated in 1999 and is based in Redwood City, California.

How the Company Makes Money

Soleno Therapeutics primarily makes money through the development and potential commercialization of its core product, DCCR tablets. The company aims to generate revenue by obtaining regulatory approval for DCCR and subsequently marketing it to healthcare providers and patients. Revenue streams are anticipated to include product sales, licensing agreements, and potential partnerships with pharmaceutical companies for distribution and commercialization. Soleno's financial performance is heavily dependent on the successful clinical development, regulatory approval, and market acceptance of its therapeutic products.

Soleno Therapeutics Financial Statement Overview

Summary

Soleno Therapeutics is in its developmental phase, with no revenue generation and substantial net losses. The company shows a strong equity base with minimal debt, but its financial health is heavily reliant on external financing due to the lack of operational cash inflow. This represents a high-risk profile typical for early-stage biotech firms.

Income Statement

Soleno Therapeutics has reported zero revenue consistently, indicating the company is yet in developmental stages with no commercialized products. The net losses have been substantial over the years, with no gross or net profit margins to evaluate, reflecting ongoing operational expenses without revenue generation. This indicates a high-risk profile typical for early-stage biotech firms.

Balance Sheet

The balance sheet shows a relatively high stockholders' equity compared to total assets, indicating a solid equity base. However, the total debt is minimal, which is positive, but the lack of revenue raises concerns about sustainability. The equity ratio is strong, but the absence of revenue impacts overall financial health adversely.

Cash Flow

Operating cash flow is negative, which is expected for a company in the biotechnology sector still in R&D phases. Free cash flow trends are also negative, highlighting ongoing cash burn without revenue inflow. Financing activities have supplemented cash flows significantly, hinting at reliance on external funding to support operations.

Breakdown	TTM	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	98.67M	0.00	0.00	0.00	0.00	0.00
Gross Profit	96.84M	0.00	-1.96M	0.00	0.00	-2.19M
EBITDA	-66.31M	-173.63M	-37.03M	-22.10M	-30.30M	-22.45M
Net Income	-78.45M	-175.85M	-38.99M	-24.07M	-30.91M	-24.64M
Balance Sheet
Total Assets	599.89M	330.97M	180.69M	26.50M	35.55M	64.98M
Cash, Cash Equivalents and Short-Term Investments	498.93M	291.44M	169.68M	14.60M	21.30M	49.22M
Total Debt	2.81M	52.83M	403.00K	155.00K	457.00K	139.00K
Total Liabilities	105.09M	85.86M	23.18M	16.15M	17.76M	19.43M
Stockholders Equity	494.81M	245.11M	157.51M	10.35M	17.79M	45.55M
Cash Flow
Free Cash Flow	-25.74M	-69.31M	-24.94M	-20.79M	-27.79M	-25.23M
Operating Cash Flow	-25.72M	-69.10M	-24.94M	-20.78M	-27.77M	-25.22M
Investing Cash Flow	-69.98M	-225.68M	0.00	-13.00K	-22.00K	-7.00K
Financing Cash Flow	293.95M	213.03M	180.02M	14.09M	-128.00K	53.72M

Soleno Therapeutics Technical Analysis

• Technical Analysis Sentiment: Negative
• Last Price: 41.95
• 50DMA: Negative
• 100DMA: Negative
• 200DMA: Negative
• MACD: Positive
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For SLNO, the sentiment is Negative. The current price of 41.95 is below the 20-day moving average (MA) of 45.98, below the 50-day MA of 47.87, and below the 200-day MA of 66.67, indicating a bearish trend. The MACD of -2.19 indicates Positive momentum. The RSI at 34.74 is Neutral, neither overbought nor oversold. The STOCH value of 22.21 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for SLNO.

Soleno Therapeutics Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
KRYS	79 Outperform	$8.18B	42.75	19.66%	―	54.51%	275.94%
ADMA	78 Outperform	$4.16B	20.33	63.17%	―	27.62%	202.89%
SLNO	53 Neutral	$2.25B	-23.06	-20.66%	―	―	44.84%
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%

Soleno Therapeutics Corporate Events

Soleno Therapeutics Announces $100M Share Buyback Plan

On November 11, 2025, Soleno Therapeutics announced that its Board of Directors approved an accelerated share repurchase agreement with Jefferies LLC to buy back $100 million of its common stock. This move reflects the company’s confidence in its commercial launch and the potential of VYKAT XR as a foundational therapy for Prader-Willi syndrome. Soleno achieved profitability in the third quarter of 2025 and views the repurchase as an attractive opportunity, with the transaction expected to conclude in the first quarter of 2026.

The most recent analyst rating on (SLNO) stock is a Buy with a $110.00 price target. To see the full list of analyst forecasts on Soleno Therapeutics stock, see the SLNO Stock Forecast page.